AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V
The transaction reflects a pre-money equity value of $400 million for AUM Biosciences -Transaction is expected to provide $69 million of gross proceeds (assuming no redemptions by Mountain Crest stockholders) -Broad pipeline of drug candidates ....